M. Jimenez

发表

Vemurafenib (VM) in non-melanoma V600 and non-V600 BRAF mutated cancers: first results of the ACSE trial

J. Blay, I. Bièche, G. Ferretti, 2016 .

Characterization of Macrophages and Osteoclasts in the Osteosarcoma Tumor Microenvironment at Diagnosis: New Perspective for Osteosarcoma Treatment?

J. Blay, P. Brousset, S. Piperno-Neumann, 2021, Cancers.

CD163-positive tumor-associated macrophages and CD8-positive cytotoxic lymphocytes are powerful diagnostic markers for the therapeutic stratification of osteosarcoma patients: An immunohistochemical analysis of the biopsies fromthe French OS2006 phase 3 trial

S. Piperno-Neumann, S. Aubert, L. Brugières, 2017, Oncoimmunology.

High-dose chemotherapy consolidation for chemosensitive advanced soft tissue sarcoma patients: an open-label, randomized controlled trial.

J. Blay, J. Coindre, S. Mathoulin-Pélissier, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Updated outcome with long-term follow-up of imatinib for the treatment of progressive or recurrent aggressive fibromatosis (desmoid tumor): A FNCLCC/ French Sarcoma Group phase II trial.

J. Blay, S. Salas, B. Bui, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Identification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosis

J. Blay, F. Bertucci, B. Bui, 2010, British Journal of Cancer.

Crizotinib in patients with advanced ROS1-rearranged non-small cell lung cancer (NSCLC). Preliminary results of the ACSé phase II trial.

G. Ferretti, S. Lantuejoul, G. Vassal, 2015 .

Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study.

J. Blay, B. Bui, C. Fournier, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High-Dose Chemotherapy and Blood Autologous Stem-Cell Rescue Compared With Standard Chemotherapy in Localized High-Risk Ewing Sarcoma: Results of Euro-E.W.I.N.G.99 and Ewing-2008.

J. Blay, U. Dirksen, A. Craft, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Somatic and Germline BRCA 1 and 2 Mutations in Advanced NSCLC From the SAFIR02-Lung Trial

I. Bièche, B. Job, J. Soria, 2020, JTO clinical and research reports.

Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study).

J. Blay, F. Collin, S. Piperno-Neumann, 2012, The oncologist.

A multicentric prospective study of intensive induction chemotherapy (API-AI) in localized osteosarcoma patients: Results of a phase II trial coordinated by the French Sarcoma Group (FSG) and the FNCLCC BECT.

J. Blay, B. Bui, A. Le Cesne, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Equal access to innovative therapies and precision cancer care

J. Blay, G. Vassal, D. Pérol, 2016, Nature Reviews Clinical Oncology.

Immune infiltrate and tumor microenvironment transcriptional programs stratify pediatric osteosarcoma into prognostic groups at diagnosis.

D. Drubay, B. Job, B. Geoerger, 2022, Cancer research.

Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up.

J. Blay, B. Bui, A. Cesne, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

An open-label, phase II study of rucaparib, a PARP inhibitor, in HER2- metastatic breast cancer patients with high genomic loss of heterozygosity: RUBY.

I. Bièche, F. André, C. Vicier, 2017 .

Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial.

G. Ferretti, G. Vassal, J. Mazières, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Final results of a FNCLCC French Sarcoma Group multicenter randomized phase II study of gemcitabine (G) versus gemcitabine and docetaxel (G+D) in patients with metastatic or relapsed leiomyosarcoma (LMS).

F. Collin, S. Piperno-Neumann, N. Penel, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Methotrexate-Etoposide-Ifosfamide Compared with Doxorubicin-Cisplatin-Ifosfamide Chemotherapy in Osteosarcoma Treatment, Patients Aged 18-25 Years.

I. Ray-Coquard, S. Piperno-Neumann, P. Kerbrat, 2019, Journal of adolescent and young adult oncology.

Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial.

G. Ferretti, G. Vassal, J. Mazières, 2019 .

New immunotherapies for high-risk non-muscle invasive bladder cancer: Current state and future perspectives

M. Jimenez, C. Cañizo, A. R. Antolín, 2020 .

RUBY: A phase II study testing rucaparib in germline (g) BRCA wild-type patients presenting metastatic breast cancer (mBC) with homologous recombination deficiency (HRD).

I. Bièche, F. André, O. Trédan, 2019, Journal of Clinical Oncology.

Prognostic impact of pulmonary nodules diagnosed at initial presentation in patients with osteosarcoma

S. Piperno-Neumann, S. Sarnacki, L. Brugières, 2022, Pediatric blood & cancer.

First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG)†.

A. Ravaud, S. Culine, B. Escudier, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Late toxicity comparison of alkylating‐based maintenance regimen with cyclophosphamide (VAC) vs ifosfamide (VAI) in Ewing sarcoma survivors treated in the randomized clinical trial Euro‐EWING99‐R1 in France

M. Toulmonde, C. Rousset-Jablonski, L. Brugières, 2022, International Journal of Cancer.

Regorafenib in patients with relapsed advanced or metastatic chordoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre phase II study

F. Bertucci, A. Italiano, A. Le Cesne, 2023, ESMO open.

Crizotinib in children and adolescents with advanced ROS1, MET, or ALK-rearranged cancer: Results of the AcSé phase II trial.

B. Geoerger, G. Vassal, M. Jimenez, 2016 .

First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG)†.

A. Ravaud, S. Culine, B. Escudier, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.